DMD and Duchenne muscular dystrophy: To address these challenges, we have developed the novel, myoblast-based therapy of Dystrophin Expressing Chimeric (DEC) cells created via PEG-mediated ex vivo fusion of myoblasts from normal and DMD-affected donors [28–34].